Kardiyovasküler Hastalıklar ve Mental Problemlerin İlişkisi

Öz

Kardiyovasküler hastalıklar (KVH) genellikle kalp ve damar sistemini etkileyen hastalıkların genel bir adıdır. Bu hastalıklar arasında koroner arter hastalığı, kalp yetmezliği, kalp krizi ve inme gibi durumlar bulunmaktadır. Son yıllarda yapılan araştırmalar, kardiyovasküler hastalıkların gelişiminde nörotransmitterlerin önemli bir rol oynadığını göstermektedir. Nörotransmitterler, sinir hücreleri arasında bilgi iletimini sağlayan kimyasal bileşiklerdir. Bu bileşiklerin kalp ve damar sistemi üzerindeki etkileri, kardiyovasküler fonksiyonları düzenleme yetenekleriyle ilgilidir. Özellikle stres, duygusal faktörler ve hormonal değişiklikler, nörotransmitter salınımını etkileyerek kardiyovasküler sistemi etkileyebilir. Stresle ilişkilendirilen nörotransmitterler, özellikle adrenalin ve noradrenalin gibi, kalp atış hızını artırabilir, kan basıncını yükseltebilir ve damar tonusunu değiştirebilir. Bu fizyolojik değişiklikler, uzun vadede kardiyovasküler hastalık riskini artırabilir. Ayrıca, kronik stresin nörotransmitter düzenlemeleri üzerindeki etkileri, inflamasyon ve oksidatif stres gibi faktörler aracılığıyla kardiyovasküler hastalıkların gelişimini tetikleyebilir. Nörotransmitterlerin kardiyovasküler sistemi etkileme mekanizmaları üzerine yapılan araştırmalar, bu iki mekanizma arasında farklı alanlarda ilişkili olduğunu ortaya koymuştur. Bu bağlamda, kardiyovasküler hastalıkların nörotransmitterlerle olan kompleks ilişkisi, hem klinik hem de deneysel çalışmalarda daha fazla araştırmayı gerektirmektedir. Bu makalenin amacı bu mekanizmalar arası ilişkiyi araştırmalarla beraber göstermektir, böylece kardiyovasküler hastalıkların önlenmesi ve tedavisinde yeni yaklaşımların geliştirilmesine katkıda bulunabilir.

Anahtar Kelimeler

• Kardiyovasküler hastalıklar
• nörotransmitter
• ruh sağlığı

Relationship Between Cardiovascular Diseases and Mental Problems

Öz

Cardiovascular disease (CVD) is a general name for diseases that usually affect the cardiovascular system. These diseases include conditions such as coronary artery disease, heart failure, heart attack and stroke. Research conducted in recent years shows that neurotransmitters play an important role in the development of cardiovascular diseases. Neurotransmitters are chemical compounds that enable the transmission of information decoupled between nerve cells. The effects of these compounds on the cardiovascular system are related to their ability to regulate cardiovascular functions. In particular, stress, emotional factors and hormonal changes can affect the cardiovascular system by affecting the release of neurotransmitters. Neurotransmitters associated with stress, especially such as adrenaline and noradrenaline, can increase heart rate, raise blood pressure, and change vascular tone. These physiological changes may increase the risk of cardiovascular disease in the long term. Also, the effects of chronic stress on neurotransmitter regulation can trigger the development of cardiovascular diseases through factors such as inflammation and oxidative stress. Research conducted on the mechanisms by which neurotransmitters affect the cardiovascular system has revealed that there is a relationship between these two mechanisms in different areas. In this context, the complex relationship of cardiovascular diseases with neurotransmitters requires further research in both clinical and experimental studies. The aim of this article is to show this inter-mechanism relationship together with research so that it can contribute to the development of new approaches to the prevention and treatment of cardiovascular diseases.

Anahtar Kelimeler

• Cardiovascular diseases
• neurotransmitter
• mental health

Kaynakça

1. 1. Dolan B. Soul searching: a brief history of the mind/body debate in the neurosciences. Neurosurgical Focus. 2007;23(1):1-7.
2. 2. Drapeau A, Marchand A, Beaulieu-Prevost D. Epidemiology of psychological distress. Mental Illnesses-Understanding, Prediction and Control. 2012;69(2):105-106.
3. 3. Chaddha A, Robinson EA, Kline-Rogers E, Alexandris-Souphis T, Rubenfire M. Mental health and cardiovascular disease. The American Journal of Medicine. 2016;129(11):1145-1148.
4. 4. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization. 2011. http://www.who.int/nmh/publications/ncd_report Yayınlanma tarihi 2011. Erişim tarihi 15 Kasım 2023.
5. 5. Türkiye İstatistik Kurumu Sağlık İstatistikleri Ölüm ve Ölüm Nedeni İstatistikleri, 2019. https://data.tuik.gov.tr/Bulten/Index?p=Olum-ve-Olum-Nedeni-Istatistikleri-2019-33710. Yayınlanma tarihi Haziran 2020. Erişim tarihi 15 Kasım 2023.
6. 6. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics update: A report from the American Heart Association. Circulation. 2011;(123):18–209.
7. 7. Smith PJ, Blumenthal JA. Psychiatric and behavioral aspects of cardiovascular disease: Epidemiology, mechanisms, and treatment. Revista Española de Cardiología (English Edition). 2011;64(10):924-933.
8. 8. Cavanagh ME, Parnavelas JG. Development of somatostatin immunoreactive neurons in the rat occipital cortex: A combined immunocytochemical‐autoradiographic study. Journal of Comparative Neurology. 1988;268(1):1-12.

9. 9. Le Douarin NM, Smith J, Le Lievre CS. From the neural crest to the ganglia of the peripheral nervous system. Annual Review of Physiology. 1981;43(1):653-671.
10. 10. Patterson PH, Chun LL. The induction of acetylcholine synthesis in primary cultures of dissociated rat sympathetic neurons: II. Developmental aspects. Developmental Biology. 1977;60(2):473-481.
11. 11. Zhang XH, Poo MM. Localized synaptic potentiation by BDNF requires local protein synthesis in the developing axon. Neuron. 2002;36(4):675-688.
12. 12. Sullivan KA, Traurig HH, Papka RE. Ontogeny of neurotransmitter systems in the paracervical ganglion and uterine cervix of the rat. The Anatomical Record. 1994;240(3):377-386.
13. 13. Verhage M, Maia AS, Plomp JJ, et al. Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science. 2000;287(5454):864-869.
14. 14. Herlenius E, Lagercrantz H. Development of neurotransmitter systems during critical periods. Experimental Neurology. 2004;(190):8-21.
15. 15. Abboud FM. The sympathetic system in hypertension. State of-the art review. Hypertension. 1982;(4):208-225.
16. 16. Trzebski A. Arterial chemoreceptor reflex and hypertension. Hypertension. 1992;(19):562-566.
17. 17. Dampney RAL. Functional organization of central nervous pathways regulating the cardiovascular system. Physiol Rev. 1994;(74):323-364.
18. 18. Zhu JN, Yung WH, Kwok-Chong Chow B, Chan YS, Wang JJ. The cerebellar-hypothalamic circuits: Potential pathways underlying cerebellar involvements in somatic-visceral integration. Brain Res Rev. 2006;(52):93-106.
19. 19. Kitchen MA, Collins HL, DiCarlo SE, Scislo TJ, O’Leary DS. Mechanisms mediating NTS P2x receptor-evoked hypotension: Cardiac output vs. total peripheral resistance. Am J Physiol Heart Circ Physiol. 2001;(281):2198-2203.
20. 20. Dampney RA, Coleman MJ, Fontes MA, et al. Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin Exp Pharmacol Physiol. 2002;(29):261-268.
21. 21. Bago M, Marson L, Dean C. Serotonergic projections to the rostroventrolateral medulla from midbrain and raphe nuclei. Brain Res. 2002;(945):249-258.
22. 22. Mathias CJ. Autonomic diseases: clinical features and laboratory evaluation. Journal of Neurology, Neurosurgery & Psychiatry. 2003;(74):31-41.
23. 23. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. Journal of the American College of Cardiology. 2008;51(18):1725-1733.
24. 24. Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic nervous system dysfunction: JACC focus seminar. Journal of the American College of Cardiology. 2019;73(10):1189-1206.
25. 25. Purves D, Augustine GJ, Fitzpatrick D, Hall W, LaMantia AS, White, L. Neurosciences. De Boeck Supérieur. 2019.
26. 26. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. The Clinical Journal of Pain. 2000;16(2):101-105.
27. 27. Sowden GL, Huffman JC. The impact of mental illness on cardiac outcomes: A review for the cardiologist. International Journal of Cardiology. 2009;132(1):30-37.
28. 28. Kyrou I, Tsigos C. Chronic stress, visceral obesity and gonadal dysfunction. Hormones 2008;(7):287-293.
29. 29. Selye H. The evolution of stress concept. Am Sci. 1973;(61):692-699.
30. 30. Tavares RF, Correa FM. Role of the medial prefrontal cortex in cardiovascular responses to acute restraint in rats. Neuroscience. 2006;(143):231-240.
31. 31. Wittstein IS. Acute stress cardiomyopathy. Curr Heart Fail Rep. 2008;(5):61-68.
32. 32. Frasure-Smith N, Lesperance F. Recent evidence linking heart diseases and depression. Can J Psychiatry. 2006;(51):730-737.
33. 33. Galynker II, Cai J, Ongseng F, Finestone H, Dutta E, Serseni D. Hypofrontality and negative symptoms in major depressive disorders. J Nucl Med. 1998;(39):608-612.
34. 34. Mayberg HS. Frontal lobe dysfunction in secondary depression. J Neuropsychiatry Clin Neurosci. 1994;(6):428-442.
35. 35. Erhardt A, Muller MB, Rodel A, et al. Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2O1aHsd mice- influence of treatment with the CRHR1-antagonist R121919/NBI 30775. J Psychopharmacol. 2009;(23):31-39.
36. 36. Shen B, Avivi YE, Todaro JF, et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men: The unique contribution of anxiety among psychologic factors. J Am Coll Cardiol. 2008;51(2):113–9.
37. 37. Skala JA, Freedland KE, Carney RM. Coronary heart disease and depression: A review of recent mechanistic research. Can J Psychiatry. 2006;51(12):738–45.
38. 38. Cohen H, Benjamin J, Geva AB, Matar MA, Kaplan Z, Kotler M. Autonomic dysregulation in panic disorder and in post-traumatic stress disorder: Application of power spectrum analysis of heart rate variability at rest and in response to recollection of trauma or panic attacks. Psychiatry Res. 2000;96(1):1–13.
39. 39. Van Cauter E, Linkowski P, Kerkhofs M, et al. Circadian and sleeprelated endocrine rhythms in schizophrenia. Arch Gen Psychiatry Apr. 1991;48(4):348–56.
40. 40. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–43.
41. 41. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002;8(1):5-12.
42. 42. Lucini D, Norbiato G, Clerici M, et al. Hemodynamic and autonomic adjustments to real life stress conditions in humans. Hypertension. 2002;(39):184–8.
43. 43. Becker LC, Pepine CJ, Bonsall R, et al. Left ventricular, peripheral vascular, and neurohumoral responses to mental stress in normal middle-aged men and women. Reference group for the psychophysiological investigations of myocardial ischemia (PIMI) study. Circulation. 1996;94:2768–77.
44. 44. Harris CW, Edwards JL, Baruch A, et al. Effects of mental stress on brachial artery flow-mediated vasodilatation in healthy normal individuals. Am Heart J. 2000;139:405–11.
45. 45. Wallen NH, Goodall AH, Li N, et al. Activation of haemostasis by exercise, mental stress and adrenaline: Effects on platelet sensitivity to thrombin and thrombin generation. Clin Sci (Lond). 1999;97:27–35.
46. 46. Von Kanel R, Bardwell WA, Berry CC, et al. Effect of Beta 2-adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress. Am Heart J. 2002;144:68–72.
47. 47. Behrendt D, Ganz P. Endothelial function: From vascular biology to clinical applications. Am J Cardiol. 2002;90:40–8.
48. 48. Spieker LE, Hurlimann D, Ruschitzka F, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation. 2002;105:2817–20.
49. 49. Ferri C, Bellini C, Desideri G, et al. Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities. Diabetologia. 1997;40:100–2.
50. 50. Von Kanel R, Mills PJ, Fainman C, et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: A biobehavioral pathway to coronary artery disease? Psychosom Med. 2001;63:531–44.
51. 51. Lampert R, Jain D, Burg MM, et al. Destabilizing effects of mental stress on ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Circulation. 2000;101:158–64.
52. 52. Eaker ED, Sullivan LM, Kelly-Hayes M, et al. Anger and hostility predict the development of atrial fibrillation in men in the Framingham offspring study. Circulation. 2004;109:1267–71.
53. 53. Williams JE, Paton CC, Siegler IC, et al. Anger proneness predicts coronary heart disease risk: Prospective analysis from the atherosclerosis risk in communities (ARIC) study. Circulation. 2000;101:2034–9.
54. 54. Knox SS, Adelman A, Ellison RC, et al. Hostility, social support, and carotid artery atherosclerosis in the National Heart, Lung, and Blood Institute family heart study. Am J Cardiol. 2000;86:1086–9.
55. 55. Williams JE, Nieto FJ, Sanford CP, et al. The association between trait anger and incident stroke risk: The atherosclerosis risk in communities (ARIC) study. Stroke. 2002;33:13–20.
56. 56. Suarez EC. Joint effect of hostility and severity of depressive symptoms on plasma interleukin-6 concentration. Psychosom Med. 2003;65:523–7.
57. 57. Phillips ML. Understanding the neurobiology of emotion perception: Implications for psychiatry. Br J Psychiatry. 2003;182:190–2.
58. 58. Minhas S, Patel JR, Malik M, Hana D, Hassan F, Khouzam RN. Mind-body connection: Cardiovascular sequelae of psychiatric illness. Current Problems in Cardiology. 2022;47(10). doi: 10.1016/j.cpcardiol.2021.100959.